A promising platform for predicting toxicity by Maria Ochoa de Olza

Get full text

Low-dose irradiation for reversing immunotherapy resistance: how to translate? by María Ochoa-de-Olza, Jean Bourhis, Fernanda G Herrera

Get full text

Dual inhibition of MEK and PI3Kβ/δ–a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer by Vicenç Ruiz de Porras, Vicenç Ruiz de Porras, Vicenç Ruiz de Porras, Adrià Bernat-Peguera, Adrià Bernat-Peguera, Clara Alcon, Fernando Laguia, Maria Fernández-Saorin, Maria Fernández-Saorin, Natalia Jiménez, Ana Senan-Salinas, Ana Senan-Salinas, Carme Solé-Blanch, Carme Solé-Blanch, Andrea Feu, Mercedes Marín-Aguilera, Juan Carlos Pardo, Juan Carlos Pardo, Juan Carlos Pardo, Maria Ochoa-de-Olza, Maria Ochoa-de-Olza, Maria Ochoa-de-Olza, Joan Montero, Begoña Mellado, Begoña Mellado, Albert Font, Albert Font, Albert Font

Get full text

Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients by Gabriela Jiménez-Valerio, Mar Martínez-Lozano, Nicklas Bassani, August Vidal, María Ochoa-de-Olza, Cristina Suárez, Xavier García-del-Muro, Joan Carles, Francesc Viñals, Mariona Graupera, Stefano Indraccolo, Oriol Casanovas

Get full text

Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes by Thierry Kuntzer, Olivier Michielin, George Coukos, Alexandre Harari, Stefan Zimmermann, Maria Ochoa de Olza, Denis Comte, Angela Orcurto, Andreas Hottinger, Benita Wolf, Blanca Navarro Rodrigo, Aymeric Auger, Virginie Zimmer, Philippe Gannon, Lana Kandalaft, Lionel Trueb

Get full text

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer by Ernest Nadal, Mansoor Saleh, Santiago Ponce Aix, Maria Ochoa-de-Olza, Sandip Pravin Patel, Scott Antonia, Yumin Zhao, Ivelina Gueorguieva, Michael Man, Shawn T. Estrem, Jiangang Liu, Emin Avsar, Wen Hong Lin, Karim A. Benhadji, Leena Gandhi, Susan C. Guba, Inmaculada Ales Diaz

Get full text

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors by Hans Gelderblom, Patrick M Forde, Aung Naing, Matthew Taylor, Jennifer Mataraza, Marcus O Butler, Todd M Bauer, Justin F Gainor, Chia-Chi Lin, Sunil Sharma, Maria Ochoa de Olza, Andrea Varga, Jan H M Schellens, Hongqian Wu, Haiying Sun, Antonio P Silva, Jason Faris, Scott Cameron

Get full text

Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study. by Iván Márquez-Rodas, Manuel Martín González, Eduardo Nagore, Cristina Gómez-Fernández, Jose Antonio Avilés-Izquierdo, Cayetana Maldonado-Seral, Virtudes Soriano, Margarita Majem-Tarruella, Virginia Palomar, Rocio Maseda, Alfonso Martín-Carnicero, Teresa Puertolas, Elena Godoy, Pablo Cerezuela, Maria Ochoa de Olza, Begoña Campos, Elisabeth Perez-Ruiz, Ainara Soria, Irene Gil-Arnaiz, Maria Gonzalez-Cao, Elisa Galvez, Ana Arance, Joaquin Belon, Luis de la Cruz-Merino, Salvador Martín-Algarra, Spanish Multidisciplinary Group of Melanoma (GEM)

Get full text

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies by Tian Zhang, Filippo de Braud, Taito Esaki, Wallace Akerley, Chrisann Kyi, Richard D Carvajal, Daniel Gusenleitner, Patrick Schöffski, Miguel Martin, David S Hong, Amy Prawira, Jürgen Krauß, Nidhi Patel, Rina Hui, Andrew Weickhardt, Niladri Roy Chowdhury, Daniel S W Tan, María Ochoa-de-Olza, John Sarantopoulos, Ross A Soo, Michela Maur, Barbara Deschler-Baier, Allen Lau, Tanay S Samant, Tyler Longmire, Catherine A Sabatos-Peyton, Radha Ramesh, Tiancen Hu, Ana Carion, Padmaja Yerramilli-Rao, Vasileios Askoxylakis, Eunice L Kwak

Get full text